KNSA:NSD-Kiniksa Pharmaceuticals Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 26.89

Change

0.00 (0.00)%

Market Cap

USD 1.92B

Volume

0.59M

Analyst Target

USD 37.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

N/A

USD 13.60B
NBIX Neurocrine Biosciences Inc

N/A

USD 11.63B
VTRS Viatris Inc

N/A

USD 9.73B
LNTH Lantheus Holdings Inc

N/A

USD 7.11B
ALKS Alkermes Plc

N/A

USD 4.74B
ALVO Alvotech

N/A

USD 2.92B
HCM HUTCHMED DRC

N/A

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

N/A

USD 2.09B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.80B
EVO Evotec SE ADR

N/A

USD 1.68B

ETFs Containing KNSA

IEEM:LSE iShares MSCI Emerging Mar.. 0.00 % 0.00 %

N/A

N/A
IQQE:F iShares MSCI EM UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
IEEM:SW iShares MSCI EM UCITS ETF.. 0.00 % 0.00 %

N/A

USD 4.96B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.95% 80% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.95% 80% B- 91% A-
Trailing 12 Months  
Capital Gain 41.15% 82% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.15% 82% B 86% B+
Trailing 5 Years  
Capital Gain 25.42% 72% C 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.42% 72% C 50% F
Average Annual (5 Year Horizon)  
Capital Gain 10.99% 49% F 68% D+
Dividend Return 10.99% 49% F 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.45% 75% C 49% F
Risk Adjusted Return 30.15% 80% B- 65% D
Market Capitalization 1.92B 88% B+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.